Activities of Urszula KRUPA related to 2018/2775(RSP)
Plenary speeches (2)
Use of cannabis for medicinal purposes (B8-0071/2019) PL
Use of cannabis for medicinal purposes (debate) PL
Institutional motions (1)
MOTION FOR A RESOLUTION on use of cannabis for medicinal purposes PDF (140 KB) DOC (57 KB)
Oral questions (1)
Use of cannabis for medicinal purposes PDF (204 KB) DOC (20 KB)
Amendments (14)
Amendment 7 #
Recital C
C. whereas Ccannabis products that are used for medicinal purposes are broadly referred to as “‘medical cannabis”’, and whereas this would, however, require a change to the names of cannabis-based drugs;
Amendment 25 #
Recital K
K. whereas there is limited evidence that cannabis or cannabinoids are effective for increasing appetite and decreasing weight loss associated with HIV/AIDS, improving clinician-measured multiple sclerosis spasticity symptoms, improving symptoms of Tourette syndrome, improving symptoms of posttraumatic stress disorder and drug-resistant epilepsy;
Amendment 30 #
Recital N
N. whereas there is no uniform standardisation system for the marking and labelling of the drugs that contain THC and CBD;
Amendment 32 #
Recital O
O. whereas there is little or no educational trainingreliable information on the impact of medical products containing THC and CBD in EU countries for medical staff - medical students, medical doctors and pharmacists, as well as social campaigns information and alerts for young people and women who have motherhood in their perspective;
Amendment 35 #
Recital O a (new)
Oa. whereas there is no intra-EU regulation concerning the placing of cannabis-based drugs on the market;
Amendment 39 #
Paragraph 1
1. Stresses the need for the Commission and national authorities to draw a clear distinction between medical cannabis- based drugs which have therapeutic applications in medicine, and other applications of cannabis;
Amendment 47 #
Paragraph 3
3. Calls on the Commission and Member States to address the regulatory and financial barriers which weigh on scientific research idefine the proper conditions to enable creditable, independent scientific research, based on a wide range of material, to be conducted on the use of cannabis for medicinal purposes;
Amendment 51 #
Paragraph 4
4. Calls on the Commission to determine the priority areas for research on cannabis for medicinal purpose-based drugs in agreement with competent authorities and drawing on pioneering researchwith regard to research carried out in other countries and focusing ion those areas which may have the greatest added-value;
Amendment 55 #
Paragraph 5
5. Calls on the Commission to develop a comprehensive strategy to ensure the highest standards for the independent research, development, authorisation, marketing, pharmacovigilance and avoidance of abuse for cannabis-based medicines; emphasises the need for standardisation and unification of products containing Cannabis-based medicines;
Amendment 62 #
Paragraph 7
7. Calls on Member States to encourage increased knowledge among medical professionals gained from independent and wide-ranging research regarding the use of such cannabis-based medicines and considerfrom secondary symptoms and allowing doctors to freely use their professional judgement to prescribe cannabis and cannabis-based medicines to patients with relevant conditions, and allow pharmacists to lawfully honour those prescriptions; highlights the need for training and access to literature for medical staff - medical students, medical doctors and pharmacists - on the results of independent scientific research;
Amendment 66 #
Paragraph 8
8. Calls on the Commission to work with Member States to improve equal access to medicinal cannabis and ensure that medical cannabis, where allowed, iscannabis-based medicines and ensure that, where allowed, medicines which are effective in treating specific conditions are covered by health insurance schemes, as is the case for other medicinal products. Asks Member States to provide safe and equal choice for patients between different types of cannabis-based medicine, while ensuring that patients are accompanied by specialised medical professionals during their treatment;
Amendment 73 #
Paragraph 9
9. Calls on Member States to secure sufficient availability of safe and controlled cannabicannabis-based medicines for medicinal purposes to cater for the actual needs; be it by local production in, by means of production by medical facilities in the Member States or bypossibly of imports;
Amendment 76 #
Paragraph 9 a (new)
9 a. Calls on the Member States to develop a mechanism prohibiting the re- export of cannabis-based medicines in order to prevent their use as narcotic, psychotropic substances;
Amendment 82 #
Paragraph 10
10. Underlines how a comprehensive regulation of medical cannabis would translate in additional resources for public authoriticannabis-based medicines, would limit the black market for medical cannabis consumptionthe consumption of cannabis-based medicines, would help control points of sale, would limit the access tof this substance tofor minors and would give a legal and safeprovide safe, legal access tofor patients for itsto their medicinal use -, with particular precautions for young people and pregnant womenthe exclusion of their use by pregnant women and with restrictions on their use by young people;